Back

The cardiovascular benefit of Lp(a) reduction: not there yet

European Heart Journal

9 November 2020
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY OTHER PREVENTIVE CARDIOLOGY Risk Factors and Prevention Pharmacology and Pharmacotherapy

Abstract

Abstract

Contributors

Angela Pirillo
Angela Pirillo

Author

Alberico Luigi Catapano
Alberico Luigi Catapano

Author

IRCCS - MultiMedica Milan , Italy

You may be interested in
thumbnail
Webinar
Lipoprotein(a): current role and future perspectives in cardiovascular medicine
31 October 2025
thumbnail
Congress Presentation
Aspirin use for prevention of cardiovascular events in patients with high lipoprotein(a): a population-based study
3 September 2019
thumbnail
Congress Presentation
Lipoprotein(a) levels and LPA genotypes are not associated with echocardiographic measures of left ventricular structure and function in the general population
1 September 2024
thumbnail
Congress Presentation
Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy
24 June 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources